These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 33807034

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL, Maher TM, Acciai V, Mounir B, Quaresma M, Zouad-Lejour L, Wells CD, De Loureiro L.
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
    Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL.
    Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
    [Abstract] [Full Text] [Related]

  • 8. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
    Li DY, Liu X, Huang JY, Hang WL, Yu GR, Xu Y.
    Ther Adv Respir Dis; 2024 May; 18():17534666241232561. PubMed ID: 38414439
    [Abstract] [Full Text] [Related]

  • 13. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U, Weber B, Sarr C, Freiwald M.
    BMC Pulm Med; 2021 Jul 21; 21(1):244. PubMed ID: 34289823
    [Abstract] [Full Text] [Related]

  • 14. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
    Fischer A, Distler J.
    Clin Rheumatol; 2019 Oct 21; 38(10):2673-2681. PubMed ID: 31423560
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
    Albera C, Verri G, Sciarrone F, Sitia E, Mangiapia M, Solidoro P.
    Biomedicines; 2021 Sep 16; 9(9):. PubMed ID: 34572422
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
    Sarkar P, Avram C, Chaudhuri N.
    Expert Rev Respir Med; 2020 Oct 16; 14(10):1001-1008. PubMed ID: 32567402
    [Abstract] [Full Text] [Related]

  • 20. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
    Kilpeläinen M, Hirvonen T, Perkonoja K, Hirsjärvi S.
    Medicina (Kaunas); 2023 Jan 31; 59(2):. PubMed ID: 36837481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.